Accessibility Menu
Schrödinger logo

Schrödinger(NASDAQ) SDGR

Current Price$14.99
Market Cap$1.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-48%
5 Year-78%
1 Year-34%
1 Month-1%
Schrödinger last closing stock price
MetricPriceDate
Last closeUSD 15.032026-07-22
Schrödinger stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.62%USD 16.272026-07-15
1 month-1.31%USD 15.232026-06-22
3 month+31.73%USD 11.412026-04-23
Year to date-15.94%USD 17.882025-12-31
1 year-33.99%USD 22.772025-07-22
3 year-72.06%USD 53.792023-07-21
5 year-78.49%USD 69.882021-07-23
Since inception-47.52%USD 28.642020-02-06

Schrödinger Financials at a Glance

Market Cap

$1.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$254.91M

Net Income (TTM)

-$103.48M

EPS (TTM)

-$1.40

P/E Ratio

-10.71

Dividend

$0.00

Beta (Volatility)

1.63 (High)

Price

$14.99

Volume

105.165

Open

$15.19

Previous Close

$15.03

Daily Range

$14.65 - $15.19

52-Week Range

$10.95 - $23.02

Estimated Earnings Date

Aug 5, 2026

About Schrödinger

Schrödinger makes software for scientists to design new medicines. Its technology helps researchers find better molecules faster than labs. The company also uses these tools to discover its own drugs.

What Schrödinger Sells

  • Software Solutions: Computational platform used for drug and materials discovery; generated $199.5 million in 2025 revenue.
  • Drug Discovery: Research programs conducted with partners or internally to find new treatments; generated $56.4 million in 2025 revenue.
  • Materials Science: Software tools for industries like aerospace and semiconductors to design new materials.
  • Enterprise Informatics: Tools like LiveDesign that allow teams to share and analyze research data collaboratively.

Recent Growth and Expansion

  • Entered a research collaboration with Novartis Pharma AG in November 2024.
  • Expanded a research partnership with Eli Lilly and Company in February 2025.
  • Earned $47.6 million in 2024 from an equity stake in Morphic Holding, Inc.
  • Broadened a multi-part agreement with Otsuka Pharmaceutical in January 2025.
  • Received grant funding from the Bill & Melinda Gates Foundation in 2024.

The Computing Advantage

The company uses physics-based simulations to predict how molecules behave before labs make them. This technology allows scientists to screen billions of compounds without performing expensive physical experiments.

Key Figures for 2025

  • Total revenue reached $255.9 million for the fiscal year 2025.
  • Software revenue rose to $199.5 million in 2025, up 11% year-over-year.
  • Net income hit $32.5 million in Q4 2025, up 180.8% from Q4 2024.
  • Free cash flow was negative $16.1 million in Q4 2025, an improvement of 49.6% year-over-year.
  • Annual contract value, which measures total software license worth, reached $198.5 million in 2025.

The Evolution of Schrödinger

Schrödinger has transitioned from a software provider to a developer of its own medical treatments. Its physics-based platform supports a growing list of partnerships while advancing an internal drug pipeline.

AI Generated • May 2, 2026

Industry

Health Care Technology

Employees

850

CEO

Ramy Farid, PhD

Headquarters

New York, NY 10036, US

SDGR Financials

Key Financial Metrics (TTM)

Gross Margin

55.33%

Operating Margin

-64.65%

Net Income Margin

-40.60%

Return on Equity

-30.85%

Return on Capital

-35.26%

Return on Assets

-16.32%

Earnings Yield

-9.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

74.72M

Volume

105.165

Avg. Volume

1.37M

Financials (TTM)

Gross Profit

$141.04M

Operating Income

-$164.80M

EBITDA

-$94.57M

Operating Cash Flow

-$145.00M

Capital Expenditure

-$3.35M

Free Cash Flow

-$148.35M

Cash & ST Invst.

$398.96M

Total Debt

$106.96M

Schrödinger Performance Analysis

Schrödinger annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 180,955,00031.2%
20232023-12-31USD 216,666,00019.7%
20242024-12-31USD 207,539,000-4.2%
20252025-12-31USD 255,869,00023.3%
Schrödinger sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-8.0%
Q32025-09-30-0.8%
Q42025-12-3160.6%
Q12026-03-31-32.8%
Schrödinger annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.1047.4%
20232023-12-31USD 0.54N/A
20242024-12-31USD -2.58N/A
20252025-12-31USD -1.41-45.4%
Schrödinger sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3028.0%
Q32025-09-3023.7%
Q42025-12-31197.8%
Q12026-03-31-284.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$58.59M

-1.6%

Gross Profit

$29.55M

-5.1%

Gross Margin

50.43%

N/A

Market Cap

$1.12BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.32M

N/A

Employees

850

N/A

Net Income

-$60.03M

-0.4%

EBITDA

-$58.14M

+0.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$398.96M

-20.3%

Total Debt

$106.96M

-7.9%

Accounts Receivable

$48.18M

+4.0%

Inventory

$0.00

N/A

Long Term Debt

$90.94M

-8.5%

Short Term Debt

$16.01M

-4.4%

Return on Assets

-16.32%

N/A

Return on Invested Capital

-35.47%

N/A

Free Cash Flow

-$17.34M

-112.1%

Operating Cash Flow

-$14.83M

-110.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AZTAAzenta, Inc.
$27.16+2.14%
OMDAOmada Health
$21.84-5.00%
EVOEvotec SE
$1.95-2.50%
TDOCTeladoc Health, Inc.
$8.92-8.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About SDGR

What is the current price of Schrödinger?

Schrödinger is trading at $15.03 per share.

What is the 52-week range for Schrödinger?

Over the past 52 weeks, Schrödinger has traded between $10.95 and $23.02.

How much debt does Schrödinger have?

As of the most recent reporting period, Schrödinger reported total debt of $106.96M.

How much cash does Schrödinger have on hand?

Schrödinger reported $267.72M in cash and cash equivalents in its most recent financial results.

What is Schrödinger’s dividend yield?

Schrödinger does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.